ANTH Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.19
Previous CloseN/A
Volume1.78K
Average Volume (3M)N/A
Market Cap
$2.62K
Enterprise Value-$2.17M
Total Cash (Recent Filing)$8.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta130.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding26,179,302
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-0.50
Enterprise Value/Market Cap-828.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit76.78
Enterprise Value/Ebitda0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ANTH FAQ
What was Anthera Pharmaceuticals’s price range in the past 12 months?
Anthera Pharmaceuticals lowest stock price was $0.01 and its highest was $0.19 in the past 12 months.
What is Anthera Pharmaceuticals’s market cap?
Anthera Pharmaceuticals’s market cap is $2.62K.
When is Anthera Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anthera Pharmaceuticals’s earnings last quarter?
Anthera Pharmaceuticals released its earnings results on Nov 06, 2017. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.58.
Is Anthera Pharmaceuticals overvalued?
According to Wall Street analysts Anthera Pharmaceuticals’s price is currently Overvalued.
Does Anthera Pharmaceuticals pay dividends?
Anthera Pharmaceuticals does not currently pay dividends.
What is Anthera Pharmaceuticals’s EPS estimate?
Anthera Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anthera Pharmaceuticals have?
Anthera Pharmaceuticals has 26,179,302 shares outstanding.
What happened to Anthera Pharmaceuticals’s price movement after its last earnings report?
Anthera Pharmaceuticals reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Anthera Pharmaceuticals?
Currently, no hedge funds are holding shares in ANTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.